US 12,698,328 B2Granted

Antibodies

AssigneeGammaDelta Therapeutics Ltd

InventorsOxana Polyakova, Oliver Nussbaumer, Adrian Hayday, Pierre Vantourout

Life of this patent

Estimating the term…

Abstract

An isolated antibody or fragment thereof, which specifically binds to a gamma variable 4 (Vγ4) chain of a γδ T cell receptor (TCR) and not to a gamma variable 2 (Vγ2) chain of a γδ TCR is provided herein. Methods of treatment and other uses of said antibodies are also provided along with methods of producing said antibodies.

Claims15

Dependent claims

An isolated anti-gamma variable 4 (anti-Vγ4) antibody or fragment thereof comprising:

(a) a heavy chain variable (VH) amino acid sequence comprising a heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO:
79, a heavy chain complementarity determining region 2 (HCDR2) of SEQ ID NO:
56 and a heavy chain complementarity determining region 3 (HCDR3) of SEQ ID NO:
10;
and
a light chain variable (VL) amino acid sequence comprising a light chain complementarity determining region 1 (LCDR1) of SEQ ID NO:
102, a light chain complementarity determining region 2 (LCDR2) of EVT and a light chain complementarity determining region 3 (LCDR3) of SEQ ID NO:
33;
(b) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
86, a HCDR2 of SEQ ID NO:
63 and a HCDR3 of SEQ ID NO:
17;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
109, a LCDR2 of QDS and a LCDR3 of SEQ ID NO:
40;
(c) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
73, a HCDR2 of SEQ ID NO:
50 and a HCDR3 of SEQ ID NO:
4;
and
a VL comprising a LCDR1 of SEQ ID NO:
96, a LCDR2 of DAS and a LCDR3 of SEQ ID NO:
27;
(d) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
83, a HCDR2 of SEQ ID NO:
60 and a HCDR3 of SEQ ID NO:
14;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
106, a LCDR2 of EIT and a LCDR3 of SEQ ID NO:
37;
(e) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
84, a HCDR2 of SEQ ID NO:
61 and a HCDR3 of SEQ ID NO:
15;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
107, a LCDR2 of RDS and a LCDR3 of SEQ ID NO:
38;
(f) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
88, a HCDR2 of SEQ ID NO:
65 and a HCDR3 of SEQ ID NO:
19;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
111, a LCDR2 of AAS and a LCDR3 of SEQ ID NO:
42;
(g) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
92, a HCDR2 of SEQ ID NO:
69 and a HCDR3 of SEQ ID NO:
23;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
115, a LCDR2 of GKN and a LCDR3 of SEQ ID NO:
46;
(h) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
71, a HCDR2 of SEQ ID NO:
48 and a HCDR3 of SEQ ID NO:
2;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
94, a LCDR2 of DAS and a LCDR3 of SEQ ID NO:
25;
(i) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
72, a HCDR2 of SEQ ID NO:
49 and a HCDR3 of SEQ ID NO:
3;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
95, a LCDR2 of AAS and a LCDR3 of SEQ ID NO:
26;
(j) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
74, a HCDR2 of SEQ ID NO:
51 and a HCDR3 of SEQ ID NO:
5;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
97, a LCDR2 of WAS and a LCDR3 of SEQ ID NO:
28;
(k) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
75, a HCDR2 of SEQ ID NO:
52 and a HCDR3 of SEQ ID NO:
6;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
98, a LCDR2 of AAS and a LCDR3 of SEQ ID NO:
29;
(l) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
76, a HCDR2 of SEQ ID NO:
53 and a HCDR3 of SEQ ID NO:
7;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
99, a LCDR2 of AAS and a LCDR3 of SEQ ID NO:
30;
(m) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
77, a HCDR2 of SEQ ID NO:
54 and a HCDR3 of SEQ ID NO:
8;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
100, a LCDR2 of LGS and a LCDR3 of SEQ ID NO:
31;
(n) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
78, a HCDR2 of SEQ ID NO:
55 and a HCDR3 of SEQ ID NO:
9;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
101, a LCDR2 of KVS and a LCDR3 of SEQ ID NO:
32;
(o) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
80, a HCDR2 of SEQ ID NO:
57 and a HCDR3 of SEQ ID NO:
11;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
103, a LCDR2 of EDN and a LCDR3 of SEQ ID NO:
34;
(p) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
81, a HCDR2 of SEQ ID NO:
58 and a HCDR3 of SEQ ID NO:
12;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
104, a LCDR2 of RDK and a LCDR3 of SEQ ID NO:
35;
(q) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
82, a HCDR2 of SEQ ID NO:
59 and a HCDR3 of SEQ ID NO:
13;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
105, a LCDR2 of DVS and a LCDR3 of SEQ ID NO:
36;
(r) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
85, a HCDR2 of SEQ ID NO:
62 and a HCDR3 of SEQ ID NO:
16;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
108, a LCDR2 of DDD and a LCDR3 of SEQ ID NO:
39;
(s) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
87, a HCDR2 of SEQ ID NO:
64 and a HCDR3 of SEQ ID NO:
18;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
110, a LCDR2 of AAS and a LCDR3 of SEQ ID NO:
41;
(t) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
89, a HCDR2 of SEQ ID NO:
66 and a HCDR3 of SEQ ID NO:
20;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
112, a LCDR2 of WAS and a LCDR3 of SEQ ID NO:
43;
(u) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
90, a HCDR2 of SEQ ID NO:
67 and a HCDR3 of SEQ ID NO:
21;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
113, a LCDR2 of EVS and a LCDR3 of SEQ ID NO:
44;
(v) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
91, a HCDR2 of SEQ ID NO:
68 and a HCDR3 of SEQ ID NO:
22;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
114, a LCDR2 of EVS and a LCDR3 of SEQ ID NO:
45;
or
(w) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
93, a HCDR2 of SEQ ID NO:
70 and a HCDR3 of SEQ ID NO:
24;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
116, a LCDR2 of GKN and a LCDR3 of SEQ ID NO:
47.

182 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/801,786Filed 24 Feb 2021
Priority: GB 200258124 Feb 2020
Published: US 2023/0090901 A123 Mar 2023
Granted: 4 Aug 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification16 codes

C07K 16/2809
Against the immunoglobulin superfamily: against the T-cell receptor -CD3 complex
A61P 35/00
Antineoplastic agents
C12N 5/0634
Vertebrate cells: cells from the blood or the immune system
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies

Family

US 2023/0090901 A1Pre-grant publication · published 23 Mar 2023
US 12,698,328 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

An isolated anti-gamma variable 4 (anti-Vγ4) antibody or fragment thereof comprising:

(a) a heavy chain variable (VH) amino acid sequence comprising a heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO:
79, a heavy chain complementarity determining region 2 (HCDR2) of SEQ ID NO:
56 and a heavy chain complementarity determining region 3 (HCDR3) of SEQ ID NO:
10;
and
a light chain variable (VL) amino acid sequence comprising a light chain complementarity determining region 1 (LCDR1) of SEQ ID NO:
102, a light chain complementarity determining region 2 (LCDR2) of EVT and a light chain complementarity determining region 3 (LCDR3) of SEQ ID NO:
33;
(b) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
86, a HCDR2 of SEQ ID NO:
63 and a HCDR3 of SEQ ID NO:
17;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
109, a LCDR2 of QDS and a LCDR3 of SEQ ID NO:
40;
(c) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
73, a HCDR2 of SEQ ID NO:
50 and a HCDR3 of SEQ ID NO:
4;
and
a VL comprising a LCDR1 of SEQ ID NO:
96, a LCDR2 of DAS and a LCDR3 of SEQ ID NO:
27;
(d) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
83, a HCDR2 of SEQ ID NO:
60 and a HCDR3 of SEQ ID NO:
14;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
106, a LCDR2 of EIT and a LCDR3 of SEQ ID NO:
37;
(e) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
84, a HCDR2 of SEQ ID NO:
61 and a HCDR3 of SEQ ID NO:
15;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
107, a LCDR2 of RDS and a LCDR3 of SEQ ID NO:
38;
(f) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
88, a HCDR2 of SEQ ID NO:
65 and a HCDR3 of SEQ ID NO:
19;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
111, a LCDR2 of AAS and a LCDR3 of SEQ ID NO:
42;
(g) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
92, a HCDR2 of SEQ ID NO:
69 and a HCDR3 of SEQ ID NO:
23;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
115, a LCDR2 of GKN and a LCDR3 of SEQ ID NO:
46;
(h) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
71, a HCDR2 of SEQ ID NO:
48 and a HCDR3 of SEQ ID NO:
2;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
94, a LCDR2 of DAS and a LCDR3 of SEQ ID NO:
25;
(i) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
72, a HCDR2 of SEQ ID NO:
49 and a HCDR3 of SEQ ID NO:
3;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
95, a LCDR2 of AAS and a LCDR3 of SEQ ID NO:
26;
(j) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
74, a HCDR2 of SEQ ID NO:
51 and a HCDR3 of SEQ ID NO:
5;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
97, a LCDR2 of WAS and a LCDR3 of SEQ ID NO:
28;
(k) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
75, a HCDR2 of SEQ ID NO:
52 and a HCDR3 of SEQ ID NO:
6;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
98, a LCDR2 of AAS and a LCDR3 of SEQ ID NO:
29;
(l) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
76, a HCDR2 of SEQ ID NO:
53 and a HCDR3 of SEQ ID NO:
7;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
99, a LCDR2 of AAS and a LCDR3 of SEQ ID NO:
30;
(m) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
77, a HCDR2 of SEQ ID NO:
54 and a HCDR3 of SEQ ID NO:
8;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
100, a LCDR2 of LGS and a LCDR3 of SEQ ID NO:
31;
(n) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
78, a HCDR2 of SEQ ID NO:
55 and a HCDR3 of SEQ ID NO:
9;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
101, a LCDR2 of KVS and a LCDR3 of SEQ ID NO:
32;
(o) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
80, a HCDR2 of SEQ ID NO:
57 and a HCDR3 of SEQ ID NO:
11;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
103, a LCDR2 of EDN and a LCDR3 of SEQ ID NO:
34;
(p) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
81, a HCDR2 of SEQ ID NO:
58 and a HCDR3 of SEQ ID NO:
12;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
104, a LCDR2 of RDK and a LCDR3 of SEQ ID NO:
35;
(q) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
82, a HCDR2 of SEQ ID NO:
59 and a HCDR3 of SEQ ID NO:
13;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
105, a LCDR2 of DVS and a LCDR3 of SEQ ID NO:
36;
(r) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
85, a HCDR2 of SEQ ID NO:
62 and a HCDR3 of SEQ ID NO:
16;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
108, a LCDR2 of DDD and a LCDR3 of SEQ ID NO:
39;
(s) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
87, a HCDR2 of SEQ ID NO:
64 and a HCDR3 of SEQ ID NO:
18;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
110, a LCDR2 of AAS and a LCDR3 of SEQ ID NO:
41;
(t) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
89, a HCDR2 of SEQ ID NO:
66 and a HCDR3 of SEQ ID NO:
20;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
112, a LCDR2 of WAS and a LCDR3 of SEQ ID NO:
43;
(u) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
90, a HCDR2 of SEQ ID NO:
67 and a HCDR3 of SEQ ID NO:
21;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
113, a LCDR2 of EVS and a LCDR3 of SEQ ID NO:
44;
(v) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
91, a HCDR2 of SEQ ID NO:
68 and a HCDR3 of SEQ ID NO:
22;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
114, a LCDR2 of EVS and a LCDR3 of SEQ ID NO:
45;
or
(w) a VH amino acid sequence comprising a HCDR1 of SEQ ID NO:
93, a HCDR2 of SEQ ID NO:
70 and a HCDR3 of SEQ ID NO:
24;
and
a VL amino acid sequence comprising a LCDR1 of SEQ ID NO:
116, a LCDR2 of GKN and a LCDR3 of SEQ ID NO:
47.

182 more elements

Facts

Application

17/801,786Filed 24 Feb 2021

Priority

GB 200258124 Feb 2020

Published

US 2023/0090901 A123 Mar 2023

Granted

4 Aug 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification16 codes

C07K 16/2809
Against the immunoglobulin superfamily: against the T-cell receptor -CD3 complex
A61P 35/00
Antineoplastic agents
C12N 5/0634
Vertebrate cells: cells from the blood or the immune system
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies